This researcher has some ideas about what we need to do to address the problem.
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.
Investigational PrEP Injection, Dosed Every Other Month, Holds Up Against Daily PrEP in Phase 3 Study
The long-acting injectable drug cabotegravir proved non-inferior to daily oral TDF/FTC for MSM and transgender women.
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.
April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.
IPERGAY scientists recommended that clinicians screen patients who request PrEP, as well as patients who are already using it, for a number of key HCV risk factors.